{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:49:52Z","timestamp":1792673392839,"version":"4.5.0"},"reference-count":51,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018712","name":"University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d Cluj Napoca","doi-asserted-by":"publisher","award":["1032\/69\/13.01.2021"],"award-info":[{"award-number":["1032\/69\/13.01.2021"]}],"id":[{"id":"10.13039\/501100018712","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Urothelial carcinoma requires frequent surveillance because of its high recurrence rate, particularly in patients with non-muscle-invasive disease. Although cystoscopy remains the standard method for diagnosis and follow-up, it is invasive, costly, and associated with patient discomfort. Urinary biomarkers have emerged as potential tools for improving surveillance and reducing unnecessary cystoscopies. Methods: We performed a narrative review of studies published between 2017 and 2026 evaluating urinary biomarkers in urothelial carcinoma. Particular attention was given to assay mechanisms, diagnostic performance, clinical applications, and integration into surveillance techniques. Results: The most extensively studied biomarkers were Xpert Bladder Cancer Monitor, Bladder EpiCheck, ADXBLADDER, and Cxbladder. Most molecular assays demonstrated higher sensitivity than urinary cytology, particularly for the detection of high-grade recurrence. Reported negative predictive values frequently exceeded 95%, suggesting potential utility in identifying patients at low risk of clinically significant recurrence. Xpert Bladder Cancer Monitor and Bladder EpiCheck were supported by the largest body of surveillance evidence, whereas Cxbladder and mutation-enhanced platforms showed promise for risk stratification and individualized follow-up. Evidence supports the use of urinary biomarkers as adjuncts to cystoscopy rather than replacements. Conclusions: Modern urinary biomarkers provide clinically useful information during the surveillance of urothelial carcinoma, especially for excluding high-grade recurrence and assisting the interpretation of equivocal findings. Future biomarker-guided surveillance strategies may reduce the burden of cystoscopy while maintaining oncological safety. Further studies are required to improve specificity and sensitivity in order to fully integrate these biomarkers into diagnostic and follow-up protocols.<\/jats:p>","DOI":"10.3390\/jcm15135183","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:51:25Z","timestamp":1783003885000},"page":"5183","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Urinary Biomarkers and Their Role in the Management of Urothelial Carcinoma: A Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6793-0016","authenticated-orcid":false,"given":"Bogdan-Petru","family":"Tichil","sequence":"first","affiliation":[{"name":"Department of Cell and Molecular Biology, Faculty of Medicine, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400349 Cluj-Napoca, Romania"},{"name":"Deva Emergency County Hospital, 330004 Deva, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8504-8032","authenticated-orcid":false,"given":"Anamaria","family":"Besleaga","sequence":"additional","affiliation":[{"name":"Deva Emergency County Hospital, 330004 Deva, Romania"},{"name":"Department of Otorhinolaryngology, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0811-0821","authenticated-orcid":false,"given":"Mihaela Laura","family":"Vica Matei","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, Faculty of Medicine, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0898-7626","authenticated-orcid":false,"given":"Adrian","family":"Florea","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, Faculty of Medicine, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"ref_1","unstructured":"Gontero, P., Baard, J., and Birtle, A. (2026). EAU Guidelines. Edn. Presented at the EAU Annual Congress London 2026, EAU Guidelines Office."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Flaig, T.W., Spiess, P.E., Abern, M., An, Y., Bangs, R., Begovic, J., Brown, J., Buyyounouski, M.K., Chan, K., and Chang, P. (2026). NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (Version 1.2026), National Comprehensive Cancer Network.","DOI":"10.6004\/jnccn.2026.0022"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Oyaert, M., Van Praet, C., Delrue, C., and Speeckaert, M.M. (2025). Novel Urinary Biomarkers for the Detection of Bladder Cancer. Cancers, 17.","DOI":"10.3390\/cancers17081283"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1756287221997183","DOI":"10.1177\/1756287221997183","article-title":"Diagnostic value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer: An update","volume":"13","author":"Folchini","year":"2021","journal-title":"Ther. Adv. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s12325-017-0518-7","article-title":"Clinical Utility of Cxbladder for the Diagnosis of Urothelial Carcinoma","volume":"34","author":"Darling","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40487-018-0059-5","article-title":"Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician\u2013Patient Real-World Clinical Data Analysis","volume":"6","author":"Lough","year":"2018","journal-title":"Oncol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/JU.0000000000003126","article-title":"Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification","volume":"209","author":"Lotan","year":"2023","journal-title":"J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Koya, M., Osborne, S., Chemasl\u00e9, C., Porten, S., Schuckman, A., and Kennedy-Smith, A. (2020). An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer. BMC Urol., 20.","DOI":"10.1186\/s12894-020-0583-0"},{"key":"ref_10","first-page":"326.e1","article-title":"Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer","volume":"41","author":"Li","year":"2023","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bju.14673","article-title":"Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer","volume":"123","author":"Soria","year":"2019","journal-title":"BJU Int."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a, K.B., Riu, F., Hernandez, A., Guilarte, C., Badia, J., and Parada, D. (2022). Usefulness of the Urine Methylation Test (Bladder EpiCheck) in Follow-Up Patients with Non-Muscle Invasive Bladder Cancer and Cytological Diagnosis of Atypical Urothelial Cells\u2014An Institutional Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133855"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mancini, M., Righetto, M., Zumerle, S., Montopoli, M., and Zattoni, F. (2020). The Bladder EpiCheck Test as a Non-Invasive Tool Based on the Identification of DNA Methylation in Bladder Cancer Cells in the Urine: A Review of Published Evidence. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186542"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Fiorentino, V., Pizzimenti, C., Franchina, M., Rossi, E.D., Tralongo, P., Carlino, A., Larocca, L.M., Martini, M., Fadda, G., and Pierconti, F. (2023). Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512489"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cncy.22657","article-title":"DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group","volume":"131","author":"Pierconti","year":"2022","journal-title":"Cancer Cytopathol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Yang, Z., Song, F., and Zhong, J. (2025). Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and Surveillance. Cancers, 17.","DOI":"10.3390\/cancers17213425"},{"key":"ref_17","unstructured":"European Association of Urology (EAU) (2024). Guidelines on Non-Muscle-Invasive Bladder Cancer, EAU Guidelines Office."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_19","first-page":"251","article-title":"Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma","volume":"10","author":"Miyake","year":"2018","journal-title":"Res. Rep. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/bco2.147","article-title":"Utility of urinary biomarkers in primary haematuria: Systematic review and meta-analysis","volume":"3","author":"Soputro","year":"2022","journal-title":"BJUI Compass"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12957-021-02359-3","article-title":"Comment on \u201cPooled analysis of Xpert bladder cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma\u201d","volume":"19","author":"Sharma","year":"2021","journal-title":"World J. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"17562872221090320","DOI":"10.1177\/17562872221090320","article-title":"Xpert bladder cancer detection as a diagnostic tool in upper urinary tract urothelial carcinoma: Preliminary results","volume":"14","author":"Trenti","year":"2022","journal-title":"Ther. Adv. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15437","DOI":"10.1038\/s41598-023-42088-z","article-title":"Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial)","volume":"13","author":"Breyer","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Fasulo, V., Paciotti, M., Lazzeri, M., Contieri, R., Casale, P., Saita, A., Lughezzani, G., Diana, P., Frego, N., and Avolio, P.P. (2022). Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under \u201cActive Surveillance\u201d for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.832835"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3390\/cancers14030618","article-title":"The Role of New Technologies in the Diagnosis and Surveillance of Non-Muscle Invasive Bladder Carcinoma: A Prospective, Double-Blinded, Monocentric Study of the XPERT Bladder Cancer Monitor and Narrow Band Imaging Cystoscopy","volume":"14","author":"Singer","year":"2022","journal-title":"Cancers"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Lozano, F., Ravent\u00f3s, C.X., Carrion, A., Dinar\u00e9s, C., Hern\u00e1ndez, J., Trilla, E., and Morote, J. (2023). Xpert Bladder Cancer Monitor for the Early Detection of Non-Muscle Invasive Bladder Cancer Recurrences: Could Cystoscopy Be Substituted?. Cancers, 15.","DOI":"10.3390\/cancers15143683"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1007\/s00345-021-03629-1","article-title":"Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up","volume":"39","author":"Roupret","year":"2021","journal-title":"World J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/bju.15418","article-title":"Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert Bladder Cancer Monitor) for surveillance in patients with non-muscle-invasive bladder cancer","volume":"128","author":"Cowan","year":"2021","journal-title":"BJU Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2478\/raon-2020-0072","article-title":"The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors","volume":"55","author":"Smrkolj","year":"2020","journal-title":"Radiol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cncy.22246","article-title":"Comparison of 2 New Real-Time Polymerase Chain Reaction\u2013Based Urinary Markers in the Follow-Up of Patients with Non\u2013Muscle-Invasive Bladder Cancer","volume":"128","author":"Trenti","year":"2020","journal-title":"Cancer Cytopathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.urolonc.2020.11.014","article-title":"Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review","volume":"39","author":"Wolfs","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/jpm11050362","article-title":"The Usefulness of Cell-Based and Liquid-Based Urine Tests in Clarifying the Diagnosis and Monitoring the Course of Urothelial Carcinoma. Identification of Novel, Potentially Actionable, RB1 and ERBB2 Somatic Mutations","volume":"11","author":"Przybylski","year":"2021","journal-title":"J. Pers. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urolonc.2022.11.008","article-title":"IBCN Seminar Series 2021: Circulating tumor DNA in bladder cancer","volume":"41","author":"Christensen","year":"2023","journal-title":"Urol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1097\/JS9.0000000000003919","article-title":"Urinary biomarkers in cancer detection: Explorations, advancements, challenges, and future directions","volume":"112","author":"Pan","year":"2026","journal-title":"Int. J. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Cheng, L., Lopez-Beltran, A., and Montironi, R. (2025). Urinary Cytology. Bladder Pathology, Wiley.","DOI":"10.1002\/9781119707677"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0090-4295(02)02136-2","article-title":"Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses","volume":"61","author":"Lotan","year":"2003","journal-title":"Urology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"922","DOI":"10.7326\/M15-0997","article-title":"Urinary biomarkers for diagnosis of bladder cancer: A systematic review and meta-analysis","volume":"163","author":"Chou","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_38","first-page":"1220","article-title":"NMP22 and bladder cancer detection: A meta-analysis","volume":"198","author":"Wang","year":"2017","journal-title":"J. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1097\/01.ju.0000067461.30468.6d","article-title":"Tumor markers in the diagnosis of primary bladder cancer: A systematic review","volume":"169","author":"Glas","year":"2003","journal-title":"J. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.euo.2019.06.006","article-title":"A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria\u2014A Prospective Multicentre Performance Evaluation of ADXBLADDER","volume":"3","author":"Dudderidge","year":"2020","journal-title":"Eur. Urol. Oncol."},{"key":"ref_41","first-page":"2125","article-title":"Evaluation of MCM5 as a urinary biomarker in bladder cancer surveillance","volume":"37","author":"Bryan","year":"2019","journal-title":"World J. Urol."},{"key":"ref_42","first-page":"784","article-title":"Increased accuracy of Xpert Bladder Cancer Monitor in surveillance of non-muscle-invasive bladder cancer","volume":"121","author":"Pichler","year":"2018","journal-title":"BJU Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.eururo.2018.11.055","article-title":"Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer","volume":"75","author":"Valenberg","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","article-title":"Performance of the Bladder EpiCheck\u2122 Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial","volume":"1","author":"Witjes","year":"2018","journal-title":"Eur. Urol. Oncol."},{"key":"ref_45","first-page":"922","article-title":"Performance characteristics of Cxbladder","volume":"119","author":"Kavalieris","year":"2017","journal-title":"BJU Int."},{"key":"ref_46","first-page":"1418","article-title":"Clinical utility of Cxbladder in hematuria evaluation and surveillance","volume":"198","author":"Lotan","year":"2017","journal-title":"J. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2019.04.035","article-title":"Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy","volume":"76","author":"Konety","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.urolonc.2007.06.002","article-title":"UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing","volume":"26","author":"Hajdinjak","year":"2008","journal-title":"Urol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/cncy.21327","article-title":"Evaluation of UroVysion and cytology for bladder cancer detection","volume":"121","author":"Dimashkieh","year":"2013","journal-title":"Cancer Cytopathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and surveillance of bladder cancer using urinary tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e32143","DOI":"10.7554\/eLife.32143","article-title":"Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy","volume":"7","author":"Springer","year":"2018","journal-title":"eLife"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5183\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:13:29Z","timestamp":1783008809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":51,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135183"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135183","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]}}}